miR-182 as a prognostic marker for glioma progression and patient survival

Lili Jiang, Pu Mao, Libing Song, Jueheng Wu, Jieting Huang, Chuyong Lin, Jie Yuan, Lianghu Qu, Shi Yuan Cheng, Jun Li*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

149 Scopus citations

Abstract

Accumulating evidence indicates that miRNA expression can be used as a diagnostic and prognostic marker for human cancers. We report that the expression level of miR-182 was markedly up-regulated in glioma cell lines and in human primary glioma specimens. Quantitative PCR analysis showed that miR-182 was significantly increased by up to 32-fold in glioma tumors compared with the adjacent nontumor brain tissues obtained from the same patient. Elevated expression of miR-182 was further identified by in situ hybridization in 248 of 253 (98%) archived human glioma biopsies tested. Statistical analysis revealed a significant correlation between miR-182 expression and World Health Organization glioma grading (P < 0.001). The cumulative 5-year survival rate of glioma patients was 51.54% (95% confidence interval, 0.435 to 0.596) in the low miR-182-expression group, whereas it was only 7.23% (95% confidence interval, 0.027 to 0.118) in the high miR-182-expression group (P = 0.001), and multivariate Cox regression analysis indicated that miR-182 expression was an independent prognostic indicator for the survival of glioma patients. Moreover, the correlations of miR-182 level with the clinical features of glioma suggested in the in situ hybridization analysis were further verified by the real-time RT-PCR analysis. Taken together, our results suggest that miR-182 could be a valuable marker of glioma progression and that high miR-182 expression is associated with poor overall survival in patients with malignant glioma.

Original languageEnglish (US)
Pages (from-to)29-38
Number of pages10
JournalAmerican Journal of Pathology
Volume177
Issue number1
DOIs
StatePublished - Jul 2010

Funding

Supported by the Ministry of Science and Technology of China (973)2005CB724605; the Natural Science Foundation of China (numbers 30670803, 30770836, 30771110, 30870963 and 30831160517); Program for New Century Excellent Talents in Universities (number NCET-07-0877); the Science and Technology Department of Guangdong Province, China (numbers 07001503, 8251008901000006 and 2008A030201006); Ministry of Education of China (number (2008)890 and number 200805580047); the Science and Technology Department of Zhuhai Municipality; Guangdong Provincial Natural Science Foundation (to J.L. and L.S.); and grants US NIH CA102011, CA130966, and ACS RSG CSM-107111 (S.-Y.C.).

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint

Dive into the research topics of 'miR-182 as a prognostic marker for glioma progression and patient survival'. Together they form a unique fingerprint.

Cite this